



# **Role of Matrix Metalloproteinase-9 in Diagnosis of Dry Eye**

Thesis

*Submitted for Partial Fulfillment  
of Master Degree in Ophthalmology*

By

***Nardeen Adel Yacoub***

*M.B., B.Ch, Cairo University*

Under Supervision of

**Prof. Dr. Ayman Abdel Moneim Gaafar**

*Professor of Ophthalmology*

*Faculty of Medicine, Ain Shams University*

**Prof. Dr. Mohamed Omar Yousif**

*Assistant Professor of Ophthalmology*

*Faculty of Medicine, Ain Shams University*

**Dr. Bassem Fayez Aziz**

*Lecturer of Ophthalmology*

*Faculty of Medicine, Ain Shams University*

*Faculty of Medicine  
Ain Shams University*

2020

# Acknowledgments

*First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.*

*I wish to express my deepest thanks, gratitude and appreciation to **Prof. Dr. Ayman Abdel Moneim Gaafar**, Professor of Ophthalmology, Faculty of Medicine, Ain Shams University, for his meticulous supervision, kind guidance, valuable instructions and generous help.*

*Special thanks are due to **Prof. Dr. Mohamed Omar Yousif**, Assistant Professor of Ophthalmology, Faculty of Medicine, Ain Shams University, for his sincere efforts, fruitful encouragement.*

*I am deeply thankful to **Dr. Bassem Fajez Aziz**, Lecturer of Ophthalmology, Faculty of Medicine, Ain Shams University, for his great help, outstanding support, active participation and guidance.*

*I would like to express my hearty thanks to all my family for their support till this work was completed.*

**Nardeen Adel Yacoub**

# List of Contents

Title	Page No.
List of Abbreviations.....	4
List of Tables.....	6
List of Figures .....	7
Introduction .....	- 1 -
Aim of the Work .....	11
Review of Literature	
▪ Anatomy of Secretory Part.....	12
▪ Physiology of Lacrimal System .....	19
▪ Dry Eye Syndrome .....	27
▪ Matrix Metalloproteinase-9 .....	51
Patients and Methods.....	57
Results.....	62
Discussion .....	74
Summary.....	79
Conclusion .....	81
References .....	82
Arabic Summary	

# List of Abbreviations

Abb.	Full term
<i>AP-1</i>	<i>Activated Protein-1</i>
<i>ATF</i>	<i>Activating Transcription Factor</i>
<i>BAFF</i>	<i>B cell Activating Factor</i>
<i>GVHD</i>	<i>Graft Versus Host Disease</i>
<i>HIV</i>	<i>Human Immunodeficiency Virus</i>
<i>HLADR</i>	<i>Human Leukocyte Antigen II</i>
<i>ICAM-1</i>	<i>Inter Cellular Adhesion Molecule-1</i>
<i>IgG</i>	<i>Immunoglobulin G</i>
<i>IL-1<math>\beta</math></i>	<i>Interlukin-1beta</i>
<i>IL-6</i>	<i>Interlukin-6</i>
<i>IL-8</i>	<i>Interlukin-8</i>
<i>INF-<math>\alpha</math></i>	<i>Interferon- <math>\alpha</math></i>
<i>LASIK</i>	<i>Laser Assisted in Situ Keratomileusis</i>
<i>LIPCOFs</i>	<i>Lid Parallel Conjunctival Folds</i>
<i>MAPK</i>	<i>Mitogen Activated Protein Kinase</i>
<i>MCT</i>	<i>Medial Canthal Tendon</i>
<i>MMP</i>	<i>Matrix Metalloproteinase</i>
<i>MUC</i>	<i>Mucins</i>
<i>NF-KB</i>	<i>Nuclear Factor Kappa light enhancer</i>
<i>NGF</i>	<i>Nerve Growth Factor</i>
<i>NSAID</i>	<i>Non- Steroidal Anti Inflammatory Drugs</i>
<i>NTR</i>	<i>Neurotrophin Receptor</i>
<i>OCT</i>	<i>Optical Coherence Tomography</i>
<i>OSDI</i>	<i>Ocular Surface Disease Index</i>
<i>PRG4</i>	<i>Proteoglycan-4</i>
<i>ROS</i>	<i>Reactive Oxygen Species</i>
<i>SAPK</i>	<i>Stress Activated Protein Kinase</i>
<i>SIgA</i>	<i>Secretory Immunoglobulin A</i>

# List of Abbreviations cont...

Abb.	Full term
<i>SP</i>	<i>Surfactant Protein</i>
<i>TBUT</i>	<i>Tear BreakupTime</i>
<i>TFF</i>	<i>Tre Foil Factor</i>
<i>TIMPs</i>	<i>Tissue Inhibitors of Metalloproteinases</i>
<i>TNF-<math>\alpha</math></i>	<i>Tumor Necrosis Factor-<math>\alpha</math></i>
<i>TrKA</i>	<i>Tyrosine Kinase receptor A</i>
<i>ZO-1</i>	<i>Zonula Occludence-1</i>

# List of Tables

Table No.	Title	Page No.
<b>Table 1:</b>	Component of lipid layer.....	22
<b>Table 2:</b>	Component of aqueous layer .....	23
<b>Table 3:</b>	Ocular Surface Disease Index .....	32
<b>Table 4:</b>	Demographic data of the study group .....	62
<b>Table 5:</b>	Data of different dry eye diagnostic tests. ....	63
<b>Table 6:</b>	Distribution and percentage of clinical examinations .....	64
<b>Table 7:</b>	Correlation between InflammDry® test results and demographic distribution of study population .....	66
<b>Table 8:</b>	Relations between results of InflammDry ® and other diagnostic tests for dry eye disease. ....	68
<b>Table 9:</b>	Relation between Meibomian gland function and InflammDry® test results.....	72

# List of Figures

Fig. No.	Title	Page No.
<b>Figure 1:</b>	Schematic drawings of tubuloalveolar structure of lacrimal gland.....	12
<b>Figure 2:</b>	Superior view of lacrimal gland .....	13
<b>Figure 3:</b>	Reflected orbital lobe of lacrimal gland with levator horn partially excised to show secretory ducts and palpebral lobe .....	14
<b>Figure 4:</b>	Approximate dimensions of the lacrimal excretory system .....	15
<b>Figure 5:</b>	Bony anatomy of lacrimal sac fossa .....	17
<b>Figure 6:</b>	Tear Film Layers .....	21
<b>Figure 7:</b>	Meibomian gland dysfunction .....	34
<b>Figure 8:</b>	Lid-parallel conjunctival folds grade 1 .....	35
<b>Figure 9:</b>	A. Rose Bengal staining in severe dry eye, B. Lissamine green in moderate dry eye .....	37
<b>Figure 10:</b>	Examination with fluorescein 1 % at the slit lamp with cobalt blue light .....	37
<b>Figure 11:</b>	Vital staining of the ocular surface in a patient with dry eye disease .....	38
<b>Figure 12:</b>	Oxford grading of corneal and conjunctival staining .....	39
<b>Figure 13:</b>	Measuring tear film break-up time to assess tear film stability .....	41
<b>Figure 14:</b>	The Schirmer test .....	42
<b>Figure 15:</b>	MMP-9 expression and synthesis .....	53
<b>Figure 16:</b>	Hyperosmolar stress causes the release of MMP .....	54
<b>Figure 17:</b>	Inflammatory kit .....	59
<b>Figure 18:</b>	Gender of the study group.....	62
<b>Figure 19:</b>	Results of InflammADry® test .....	64
<b>Figure 20:</b>	Meibomian glands assessment.....	65
<b>Figure 21:</b>	Relation between InflammADry® results and different sex .....	67

# List of Figures cont...

Fig. No.	Title	Page No.
<b>Figure 22:</b>	Relation between inflammaDry® results and mean of age.....	67
<b>Figure 23:</b>	Relation between Ocular Surface Disease Index (OSDI) and InflammDry® test results.....	69
<b>Figure 24:</b>	Relation between corneal staining and InflammDry® results .....	70
<b>Figure 25:</b>	Relation between Schirmer test, Tear breakup time and InflammDry® results.....	71
<b>Figure 26:</b>	Relation between Meibomian glands assessment and InflammDry® results. ....	73

## INTRODUCTION

Dry eye is a “multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface” (*Foulks et al., 2007*).

Symptoms of dry eye, which include visual disturbances and pain, have been found to negatively impact quality of life (*Pouyeh et al., 2012*).

Due to the multifactorial etiology of dry eye and its varied pathophysiologic mechanisms, it has been difficult to identify specific biomarkers that can aid in the diagnosis of dry eye. Inflammation is known to play an important role in the initiation and propagation of dry eye (*Sambursky et al., 2014*).

Matrix Metalloproteinase-9 (MMP-9) is a zinc and calcium ion-dependent enzyme important for tissue remodeling in normal physiological processes like wound healing and bone development. It plays a pathogenic role in inflammatory disease, arthritis, cardiovascular diseases, pulmonary diseases, and cancer (*Lanza et al., 2016*).

MMP-9 activity is regulated by epigenetic processes, cell-cell interactions, and cytokine-mediated pathways. On the corneal surface, the hyperosmolarity of the tear fluid seen in dry eye has been shown to trigger the stress-activated protein kinase (SAPK) signaling cascade. SAPK signaling leads to the

release of MMP-9 from corneal epithelial cells themselves, thus initiating a cycle of progressive inflammation. Tight junction proteins; occludin and zonula occludens-1 (ZO-1) are cleaved by MMP-9, thereby disrupting epithelial layers (*Aragona et al., 2015*).

T-cell recruitment, the proteolytic activity of the MMP-9 molecule itself, and activation of secretion of additional cytokines initiate a self-perpetuating cycle of inflammation, secretory dysfunction, and worsening eye dryness (*Hessen and Akpek, 2014*).


In this study, we will use InflammDry (RPS, Sarasota, FL), a novel test to measure level of MMP-9. It measures the presence of MMP-9. The test provides a qualitative (yes/no) response. The lower detection limit of the test is 40 ng/ml. If the collected sample is less than 5  $\mu$ L, the test may falsely give a negative result (*Sambursky et al., 2013*).

## **AIM OF THE WORK**

To assess the presence of ocular surface matrix metalloproteinase-9 (MMP-9) in dry eye by InflammDry<sup>®</sup> test.

**Chapter 1****ANATOMY OF LACRIMAL SYSTEM****Anatomy of secretory part****1- Main lacrimal gland**

The main lacrimal gland is located in the superotemporal part of orbit in a shallow lacrimal fossa of the frontal bone. The gland is composed of numerous acini which drain into larger tubules and ducts. The acini are made up of a basal contractile myoepithelial cell layer with inner columnar secretory cells (figure 1) (*Lemke and Lucarelli, 2012*).



**Figure 1:** Schematic drawings of tubuloalveolar structure of lacrimal gland (*Lemke and Lucarelli, 2012*).


The gland measures  $20 \times 12 \times 5$  mm and the lateral horn of the levator aponeurosis divides it into a larger orbital lobe, and a lesser palpebral lobe below (figure 2). The orbital lobe

lies posterior to the orbital septum and preaponeurotic fat and anterior to the levator aponeurosis (*Dutton, 1994*).



**Figure 2:** Superior view of lacrimal gland (*Lemke and Lucarelli, 2012*).

Two to six secretory ducts from the orbital lobe of the lacrimal gland pass through the palpebral lobe or along its fibrous capsule (figure 3), joining with ducts from the palpebral lobe to form 6–12 tubules that empty into the superolateral conjunctival fornix 4–5 mm above the tarsus (*Lemke and Lucarelli, 2012*).



**Figure 3:** Reflected orbital lobe of lacrimal gland with levator horn partially excised to show secretory ducts and palpebral lobe (*Lemke and Lucarelli, 2012*).

## 2- Accessory Lacrimal Glands

Accessory lacrimal glands are located in the conjunctival fornices and along the superior tarsal border. There are approximately 20–40 accessory glands of Krause in the superior conjunctival fornix, and half that number present in the lower eyelid. Accessory glands of Wolfring are located along the superior tarsal border in the upper eyelid (*Seifert et al., 1994*).

### Anatomy of excretory part


#### 1- Lacrimal punctum

The lacrimal punctum lies on lacrimal papilla a small fibrous mound (figure 4). It measures 0.2–0.3 mm in diameter and directs posteriorly toward the ocular surface. The inferior

punctum lies 0.5– 1.0 mm more temporally than the superior one. The inner epithelium is nonkeratinized stratified squamous epithelium. No Meibomian glands exist medial to the papillae, and most medial Meibomian orifices are situated at 0.5–1.0 mm lateral to the puncta (*Kakizaki and Valenzuela, 2011*).

## 2- Lacrimal canaliculus

The lacrimal canaliculus is divided into vertical and horizontal portions. The vertical portion length is 2 mm and the horizontal part is 10 mm (figure 4), the punctum and vertical canaliculus are encircled by hard fibrous tissue. This fibrous tissue contains the muscle of Riolan. The epithelium of the canaliculus is a nonkeratinized stratified squamous epithelium. The temporal 4/5 part is surrounded by the Horner's muscle (*Kakizaki et al., 2012*).



**Figure 4:** Approximate dimensions of the lacrimal excretory system (BE bulla ethmoidalis, IT inferior turbinate, MS maxillary sinus, MT middle turbinate) (*Lemke and Lucarelli, 2012*).